Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/5/2019
Start Date:August 30, 2018
End Date:August 30, 2021
Contact:Gretchen Macmillan
Email:gretchen.macmillan@moffitt.org
Phone:813-745-8443

Use our guide to learn which trials are right for you!

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients With HPV+ Oropharyngeal Cancers

This study is to determine whether a mathematical model can be used to choose a radiation
delivery method to improve the rate of a rapid response.

Investigators hypothesize that using individual patient proliferation saturation index (PSI)
to select radiotherapy fractionation (conventional fractionation or hyperfractionation) may
improve the likelihood of a rapid response (defined as ≥ 32% reduction in volume at 4 weeks).

Inclusion Criteria:

- Stated willingness to comply with all study procedures and availability for the
duration of the study

- Male or female, aged ≥ 18 years

- Pathologically (histologically or cytologically) proven diagnosis of p16+ or HPV+
squamous cell carcinoma (including the histological variants papillary squamous cell
carcinoma and basaloid squamous cell carcinoma) of the oropharynx; cytologic diagnosis
from a cervical lymph node is sufficient in the presence of clinical evidence of a
primary tumor in the oropharynx. Clinical evidence should be documented, and may
consist of pathology, palpation, imaging, or endoscopic evaluation, and should be
sufficient to estimate the size of the primary (for T stage).

- American Joint Committee on Cancer (AJCC) 8th edition staging T1-3 N0-1 MO

- Patients must have clinically or radiographically evident measurable disease at the
primary site or at nodal stations.

- CT or MRI performed at least 1 week apart. This can consist of diagnostic imaging and
radiation therapy planning imaging.

- No evidence of distant metastases

- Eastern Cooperative Oncology Group Performance Status 0 to 3

Exclusion Criteria:

- Age < 18

- Positive urine pregnancy test

- Evidence of distant metastases

- Gross total excision of both primary and nodal disease; this includes tonsillectomy,
local excision of primary site, and nodal excision that remove all clinically and
radiographically evident disease

- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields

- Patients with a medical condition or social situation that at the discretion of the PI
would preclude them from completion of the trial
We found this trial at
1
site
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Jimmy Caudell, MD, PhD
Phone: 813-745-8443
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials